Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 5
2006 1
2008 1
2009 5
2010 9
2011 11
2012 17
2013 14
2014 16
2015 15
2016 16
2017 17
2018 13
2019 16
2020 25
2021 32
2022 32
2023 15
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20501908

213 results

Results by year

Filters applied: . Clear all
Page 1
18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, Haense C, Richardson AM, Gerhard A, Anton-Rodriguez JM, Snowden JS, Neary D, Pontecorvo MJ, Herholz K. Kobylecki C, et al. J Nucl Med. 2015 Mar;56(3):386-91. doi: 10.2967/jnumed.114.147454. Epub 2015 Feb 5. J Nucl Med. 2015. PMID: 25655625 Free article.
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de La Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, Gissot V, Vierron E, Vercouillie J, Vellas B, Eustache F, Guilloteau D. Camus V, et al. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31. doi: 10.1007/s00259-011-2021-8. Epub 2012 Jan 18. Eur J Nucl Med Mol Imaging. 2012. PMID: 22252372 Free PMC article. Clinical Trial.
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Fleisher AS, et al. Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150. Epub 2011 Jul 11. Arch Neurol. 2011. PMID: 21747008
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles.
Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, Reynders T, Telan-Choing NF, Riffel K, Celen S, Serdons K, Bormans G, Tsai K, Walji A, Hostetler ED, Evelhoch JL, Van Laere K, Forman M, Stoch A, Sur C, Struyk A. Lohith TG, et al. J Nucl Med. 2019 Jan;60(1):107-114. doi: 10.2967/jnumed.118.208215. Epub 2018 Jun 7. J Nucl Med. 2019. PMID: 29880509 Free article.
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM; Florbetapir F 18 Study Investigators. Joshi AD, et al. J Nucl Med. 2012 Mar;53(3):378-84. doi: 10.2967/jnumed.111.090340. Epub 2012 Feb 13. J Nucl Med. 2012. PMID: 22331215 Free article.
213 results